Samsung Bioepis secures 10-year exclusive drug supply deal in Brazil

Samsung Bioepis has secured a 10-year exclusive supply deal for its rare disease treatment, SB12, in Brazil, marking a significant milestone for the Korean biopharmaceutical company in the Latin American market. The agreement, which involves supplying SB12, a biosimilar of Soliris, to Brazil’s Ministry of Health, underscores Samsung Bioepis' commitment to strengthening its presence in the region.

This partnership, facilitated under the Brazilian government's Productive Development Partnership program, is expected to provide a stable revenue stream for Samsung Bioepis, capitalizing on the $170 million market value for eculizumab in Brazil.

Brief written by urgent.news from The Korea Times's own syndicated text. Machine-written — may contain errors; check the original before relying on it.